-5.5%
ROP vs GSK
+65.2%
-70.7%
-46.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | +2.4% | -3.4% | -1.4% |
| 7D | -1.6% | +4.9% | -6.6% | -2.3% |
| 30D | +29.5% | +10.8% | +18.7% | +27.8% |
| 3M | +17.5% | -1.8% | +19.3% | +17.6% |
| 6M | +38.1% | +4.1% | +34.0% | +37.2% |
| YTD | +7.0% | +7.9% | -0.9% | +5.5% |
| 1Y | +6.5% | +14.4% | -7.9% | +4.3% |
| 3Y | -5.5% | +68.1% | -73.6% | -12.0% |
| All | -5.5% | +65.2% | -70.7% | -12.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling